Crystalys gets $130M to take Sobi-rivaling gout drug to market
A San Diego biotech has raised an additional $130 million to get a gout drug that's already approved in Japan and China onto the US and European markets. Crystalys Therapeutics reeled in the Series B ...
James Mackay, Crystalys Therapeutics CEO July 22, 2026 08:00 AM EDT FinancingStartups Crystalys gets $130M to take Sobi-rivaling gout drug to market Kyle LaHucik Biotech Correspondent A San Diego biotech has raised an additional $130 million to get a gout drug that’s already approved in Japan and China onto the US … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that